Does TRT Help with Inflammation? What Research Shows

Testosterone replacement therapy (TRT) can lower multiple markers of inflammation in men with diagnosed testosterone deficiency. A 2019 systematic review in the Journal of the Endocrine Society found that low testosterone correlates with increased pro-inflammatory cytokines and that restoring levels through TRT may reduce them. TRT isn't an anti-inflammatory drug. But correcting a hormone deficiency appears to remove one driver of chronic, low-grade inflammation.

Patients working with a telehealth hormone provider often ask about these effects. TRT has been shown to reduce pro-inflammatory cytokines including TNF-alpha and IL-1beta, as well as the inflammatory marker C-reactive protein (CRP), in men with testosterone deficiency, while raising the anti-inflammatory cytokine IL-10. These changes have been studied primarily in men who also have type 2 diabetes or metabolic syndrome.

Chronic inflammation contributes to cardiovascular disease, type 2 diabetes, autoimmune disorders, and certain cancers. When testosterone levels decline below 300 ng/dL on two separate morning draws (a reasonable cut-off per the AUA guideline), the body's inflammatory markers may be higher. The studies covered here break down the specific mechanisms behind TRT's anti-inflammatory effects and what the data supports.

Testosterone and Inflammatory Cytokines

Cytokines are small proteins that act as signals in the immune system. Some drive inflammation. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) are two of the most studied pro-inflammatory cytokines. Others, like interleukin-10 (IL-10), work to suppress the inflammatory response.

C-reactive protein (CRP) is another widely used inflammation marker. The liver produces CRP in response to inflammatory signals, and high levels appear in conditions ranging from cardiovascular disease to rheumatoid arthritis. Clinicians often measure both cytokines and CRP to assess a patient's inflammatory status.

A 2019 systematic review on testosterone's anti-inflammatory properties found that testosterone inhibits adipose tissue formation and suppresses multiple pro-inflammatory markers. Low testosterone correlated with increased TNF-alpha, IL-6, and IL-1. Higher testosterone levels correlated with increased adiponectin, an anti-inflammatory protein produced by fat cells. In hypogonadal men receiving TRT, studies showed reductions in TNF-alpha and IL-1beta alongside increases in IL-10.

These aren't abstract lab numbers. High TNF-alpha and IL-6 are tied to atherosclerosis, insulin resistance, and increased mortality risk. Men who want to understand how their free and total testosterone interact with inflammatory markers should discuss targeted blood work with their provider.

How Does TRT Affect Insulin Resistance?

Insulin resistance and inflammation feed each other. When cells stop responding to insulin, the body produces more inflammatory mediators. Those mediators make insulin resistance worse. This cycle accelerates the progression toward type 2 diabetes and metabolic syndrome.

An estimated 25% to 40% of men with type 2 diabetes also have low testosterone. A 2016 study published in Diabetes Care examined 94 men with type 2 diabetes. Forty-four of them had hypogonadotropic hypogonadism and were randomized to TRT or placebo for 24 weeks. The TRT group experienced a 32% increase in insulin-stimulated glucose uptake. They lost about 3 kilograms of fat mass and gained 3 kilograms of lean body mass, with no net change in body weight.

That same study documented decreases in free fatty acids, CRP, IL-1beta, and TNF-alpha in the TRT group. These reductions in inflammatory markers happened alongside improved insulin sensitivity. The data suggest the two effects are connected. For men managing both metabolic health and TRT, this data points to measurable, overlapping benefits when a deficiency is properly corrected.

Testosterone's Direct Effect on Hepcidin

Hepcidin is a peptide hormone produced by the liver that regulates iron metabolism. Under normal conditions, it keeps iron levels balanced by controlling absorption from food and release from storage sites. Iron is the building block of red blood cells, and hepcidin makes sure the body has enough without accumulating too much.

During chronic inflammation or infection, hepcidin production spikes. High hepcidin blocks iron absorption and locks iron inside storage cells. This leads to anemia of chronic disease, marked by persistent fatigue and weakness. Beyond anemia, high hepcidin has been connected to atherosclerosis. It traps iron in vascular plaque macrophages, which promotes foam cell formation and plaque instability.

A 2023 randomized, double-blinded, placebo-controlled study published in Biomedicines tested whether TRT could lower hepcidin in men with type 2 diabetes. Thirty-nine men aged 50 to 70 were enrolled. Twenty received testosterone gel and 19 received placebo for 24 weeks. The TRT group saw hepcidin levels drop by 9.5 ng/mL (p < 0.001) compared to placebo. Lean body mass increased by 1.9 kg and fat mass decreased by 1.3 kg.

The reduction in hepcidin wasn't linked to changes in iron levels or body composition. The researchers suggested this may indicate a direct anti-inflammatory effect of testosterone on hepcidin, though they noted the interpretation remains speculative. If confirmed in larger trials, this would suggest testosterone may act on inflammatory pathways independent of body composition changes.

What the Research Means for Chronic Disease

The evidence supports that TRT can reduce several inflammatory markers in men with diagnosed testosterone deficiency. But these findings come from studies on hypogonadal men, not the general male population. No clinical guidelines recommend TRT as a treatment for inflammation alone.

What the data does support is that correcting a deficiency may lower one contributing factor to chronic inflammation. Since chronic inflammation drives cardiovascular disease, type 2 diabetes, autoimmune conditions, and certain cancers, TRT could be considered as part of a broader treatment plan, in consultation with a licensed provider, for at-risk men.

Research from West Virginia University provides added context. A 2021 animal study published in Gastroenterology found that androgens protected mice from stomach inflammation. When researchers gave testosterone to female mice lacking both glucocorticoids and androgens, their stomach inflammation resolved completely in this animal model. Lead researcher Jonathan Busada noted that 8 out of 10 individuals with autoimmune disease are women and that androgens may provide a "double layer of protection" from inflammatory response.

Men asking whether TRT helps with inflammation should also weigh the risks. The FDA updated testosterone labeling in February 2025 after the TRAVERSE trial. The agency removed the cardiovascular black-box warning but added a new blood pressure warning. Other documented side effects include increased hematocrit (polycythemia rates on TRT range from 2.5% to over 40% depending on formulation and dose), acne, fluid retention, and estradiol changes. The AUA guideline requires ongoing lab monitoring for anyone on TRT. Regular blood work isn't optional. Testosterone is FDA-approved only for men with diagnosed hypogonadism due to a specific medical condition, not for age-related testosterone decline.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Does TRT help with inflammation?

Research supports that TRT may lower pro-inflammatory markers like TNF-alpha and IL-1beta, as well as C-reactive protein, in men with diagnosed testosterone deficiency. A 2019 systematic review in the Journal of the Endocrine Society reported these findings. TRT is not approved as an anti-inflammatory treatment, but correcting a hormone deficiency may reduce one contributing factor to chronic inflammation.

How long does TRT take to lower inflammation?

Anti-inflammatory effects of TRT may begin to appear within 3 to 12 weeks, based on published timelines for inflammatory marker changes. Full stabilization may take 12 weeks or longer. Individual response depends on baseline hormone levels, severity of deficiency, and the presence of conditions like type 2 diabetes.

Can testosterone reduce C-reactive protein levels?

A 2016 study of 94 men with type 2 diabetes and hypogonadism found that 24 weeks of TRT reduced CRP alongside other inflammatory markers. These reductions occurred with improved insulin sensitivity and body composition changes, including a loss of 3 kg of fat mass and a gain of 3 kg of lean mass.

Does low testosterone cause inflammation?

Low testosterone is associated with higher levels of pro-inflammatory cytokines like TNF-alpha and IL-6. A systematic review found that men with low testosterone had higher inflammatory markers compared to men with normal levels. Whether low testosterone directly causes inflammation or contributes to a pro-inflammatory state alongside other factors is still being studied.

Is TRT safe for men with chronic inflammatory conditions?

TRT carries documented risks including increased hematocrit, blood pressure changes, and estradiol shifts, regardless of a patient's inflammatory status. The FDA updated testosterone labeling in 2025 to reflect new safety data from the TRAVERSE trial. Any man considering TRT should undergo an evaluation by a licensed provider and commit to ongoing lab monitoring.

What blood tests measure inflammation during TRT?

Common markers include C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta). Hepcidin may also be tested in specific clinical contexts. These are typically ordered alongside standard TRT monitoring panels that include hematocrit, PSA, estradiol, and lipid levels.

References

• J Endocr Soc. 2019;3(1):91–107

• Diabetes Care. 2016;39(1):82–91

• Biomedicines. 2023;11(12):3184

• Gastroenterology. 2021;161(2):637–652.e11

• J Urol. 2018;200(2):423–432

• Eur J Endocrinol. 2011;165(5):675–685

• N Engl J Med. 2023;389(2):107–117